Search

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
GET IN TOUCH
Solutions Small Molecules Discovery Integrated Drug Discovery Modalities Protein or RNA

Protein or RNA

RNA and Protein Degrader/Modulator Modalities of Small Molecules

In the evolving landscape of drug discovery, RNA and protein degrader/modulator modalities have emerged as revolutionary approaches in small-molecule therapeutics. These strategies offer a pathway to tackle previously “undruggable” targets and expand therapeutic horizons across multiple disease areas.

At Aragen Life Sciences, we empower innovation in Integrated Drug Discovery (IDD) by advancing RNA and protein degrader/modulator platforms. Our expertise transforms challenging drug targets into therapeutic realities, enabling breakthroughs across oncology, CNS disorders, inflammation, metabolic diseases, and more.

RNA-Targeting Small Molecules

Small molecules targeting RNA are reshaping the therapeutic landscape by modulating gene expression at its source. These molecules can:

  • Inhibit RNA-protein interactions, disrupting pathways critical for disease progression.
  • Modulate RNA splicing to restore proper protein function or reduce the production of pathogenic variants.
  • Induce RNA degradation through innovative mechanisms like RIBOTACs (ribonuclease-targeting chimeras), selectively eliminating disease-driving RNA transcripts.

Applications span oncology, rare genetic disorders, metabolic diseases, and infectious diseases, offering precision intervention at the molecular level.

Comprehensive Support for Next-Generation Modalities

As a Contract Research Organization (CRO), we offer end-to-end support in RNA and protein degrader/modulator development, including:

  • High-throughput screening to identify lead compounds.
  • Advanced biophysical and cellular assays for mechanistic validation.
  • Structure-based design leveraging cutting-edge technologies.
  • In vivo models to evaluate efficacy and safety profiles.

Partner with Aragen to access integrated discovery support for RNA and protein modulation programmes.